ABT-925 Fumarate | CAS# 220519-07-3 | Dopamine D3 receptor antagonist

MedKoo Cat#: 574547 | Name: ABT-925 fumarate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ABT-925, also known as A-37203, BSF-201640; DAT-201; Lu-201640; and A-437203, is a selective dopamine D3 receptor (DRD3) antagonist with an approximately 100-fold higher in vitro affinity for dopamine D₃ versus D₂ receptors. ABT-925 was tested in schizophrenia. ABT-925 is a selective dopamine D₃ receptor antagonist with an approximately 100-fold higher in vitro affinity for dopamine D₃ versus D₂ receptors.

Chemical Structure

ABT-925 fumarate

CAS#220519-07-3 (fumarate)

Theoretical Analysis

MedKoo Cat#: 574547

Name: ABT-925 fumarate

CAS#: 220519-07-3 (fumarate)

Chemical Formula: C24H31F3N6O5S

Exact Mass: 572.2029

Molecular Weight: 572.60

Elemental Analysis: C, 50.34; H, 5.46; F, 9.95; N, 14.68; O, 13.97; S, 5.60

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

1160247-85-7 (fumarate hydrate) 220519-06-2 (free base) 220519-07-3 (fumarate) ABT-925 HCl

Synonym

A 37203; A-37203; A37203; A 437203; A437203; A-437203; ABT 925; ABT925; ABT-925; BSF 201640; BSF201640; BSF-201640; DAT 201; DAT201; DAT-201; Lu 201640; Lu201640; Lu-201640;

IUPAC/Chemical Name

2-[[3-[4-[2-(1,1-Dimethylethyl)-6-(trifluoromethyl)-4-pyrimidinyl]-1-piperazinyl]propyl]thio]-4(1H)-pyrimidinone (2E)-2-Butenedioate

InChi Key

KQMGYGQUUXCWBL-WLHGVMLRSA-N

InChi Code

InChI=1S/C20H27F3N6OS.C4H4O4/c1-19(2,3)17-25-14(20(21,22)23)13-15(26-17)29-10-8-28(9-11-29)7-4-12-31-18-24-6-5-16(30)27-18;5-3(6)1-2-4(7)8/h5-6,13H,4,7-12H2,1-3H3,(H,24,27,30);1-2H,(H,5,6)(H,7,8)/b;2-1+

SMILES Code

O=C1N=C(SCCCN2CCN(C3=NC(C(C)(C)C)=NC(C(F)(F)F)=C3)CC2)NC=C1.O=C(O)/C=C/C(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 572.60 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Kehr J, Wang FH, Ichinose F, Yoshitake S, Farkas B, Kiss B, Adham N. Preferential Effects of Cariprazine on Counteracting the Disruption of Social Interaction and Decrease in Extracellular Dopamine Levels Induced by the Dopamine D3 Receptor Agonist, PD-128907 in Rats: Implications for the Treatment of Negative and Depressive Symptoms of Psychiatric Disorders. Front Psychiatry. 2022 Jan 12;12:801641. doi: 10.3389/fpsyt.2021.801641. PMID: 35095615; PMCID: PMC8789685. 2: Pich EM, Collo G. Pharmacological targeting of dopamine D3 receptors: Possible clinical applications of selective drugs. Eur Neuropsychopharmacol. 2015 Sep;25(9):1437-47. doi: 10.1016/j.euroneuro.2015.07.012. Epub 2015 Jul 21. PMID: 26298833. 3: Bhathena A, Wang Y, Kraft JB, Idler KB, Abel SJ, Holley-Shanks RR, Robieson WZ, Spear B, Redden L, Katz DA. Association of dopamine-related genetic loci to dopamine D3 receptor antagonist ABT-925 clinical response. Transl Psychiatry. 2013 Apr 9;3(4):e245. doi: 10.1038/tp.2013.22. PMID: 23571810; PMCID: PMC3641409. 4: Gross G, Wicke K, Drescher KU. Dopamine D₃ receptor antagonism--still a therapeutic option for the treatment of schizophrenia. Naunyn Schmiedebergs Arch Pharmacol. 2013 Feb;386(2):155-66. doi: 10.1007/s00210-012-0806-3. Epub 2012 Nov 6. PMID: 23128852. 5: Redden L, Rendenbach-Mueller B, Abi-Saab WM, Katz DA, Goenjian A, Robieson WZ, Wang Y, Goss SL, Greco N 4th, Saltarelli MD. A double-blind, randomized, placebo-controlled study of the dopamine D₃ receptor antagonist ABT-925 in patients with acute schizophrenia. J Clin Psychopharmacol. 2011 Apr;31(2):221-5. doi: 10.1097/JCP.0b013e31820e4818. PMID: 21346607. 6: Wan K, Rieser M, El-Shourbagy T. Quantitative Determination of ABT-925 in Human Plasma by On-Line SPE and LC-MS/MS: Validation and Sample Analysis in Phase II Studies. Pharmaceutics. 2010 May 4;2(2):171-181. doi: 10.3390/pharmaceutics2020171. PMID: 27721349; PMCID: PMC3986714. 7: Day M, Bain E, Marek G, Saltarelli M, Fox GB. D3 receptor target engagement in humans with ABT-925 using [11C](+)-PHNO PET. Int J Neuropsychopharmacol. 2010 Apr;13(3):291-2. doi: 10.1017/S1461145710000180. Epub 2010 Mar 3. PMID: 20196920. 8: Graff-Guerrero A, Redden L, Abi-Saab W, Katz DA, Houle S, Barsoum P, Bhathena A, Palaparthy R, Saltarelli MD, Kapur S. Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925. Int J Neuropsychopharmacol. 2010 Apr;13(3):273-87. doi: 10.1017/S1461145709990642. Epub 2009 Sep 15. PMID: 19751545.